Cancer Treatment Today

Clofarabine is a deoxyadenosine analogue, which has shown significant single-agent activity in patients who have failed or are resistant to conventional treatment, including cladrabine. There are small studies and case reports reporting activity. The most recent study of 18 patient by Simko et al, concluded that Clofarabine has activity against LCH, JXG, and RDD in heavily pretreated patients, but prospective multi-center trials are warranted to determine long-term efficacy, optimal dosing, and late toxicity of clofarabine in this population. A phasae II trial that is starting is trials are just beginning, for example, NCT01796405, a phase II.

Rodriguez-Galindo et al, . Clofarabine in refractory Langerhans cell histiocytosis. Pediatr Blood Cancer 2008;51:703-6.

Abraham A, Alsultan A, Jeng M, Rodriguez-Galindo C, Campbell PK. Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis. Pediatr Blood Cancer. 2013 Jun;60(6):E19-22.

Simko SJ, Tran HD, Jones J, Bilgi M, Beaupin LK, Coulter D, Garrington T, McCavit TL, Moore C, Rivera-Ortegón F, Shaffer L, Stork L, Turcotte L, Welsh EC, Hicks MJ, McClain KL, Allen CE.Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2014 Mar;61(3):479-87.

Gadner H, Grois N, Pötschger U, et al.: Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 111 (5): 2556-62, 2008.

Gadner H, Minkov M, Grois N, et al.: Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood 121 (25): 5006-14, 2013. Not certify Left a message on Dr. Doners line at 11:30 AM on 6/30/14.